In the interview, Susan Pandya, MD, Vice President of Clinical Development at Servier Pharmaceuticals, discusses the pivotal FDA acceptance and priority review for TIBSOVO in the treatment of IDH1-mutated relapsed or refractory myelodysplastic syndromes (MDS). The acceptance marks a significant milestone in advancing targeted therapies for patients facing limited options in this challenging disease context.
TIBSOVO’s clinical data submission showcased remarkable results, with complete remissions achieved in approximately 40% of patients and an overall response rate of 83.3% among those with relapsed or refractory IDH1-mutated MDS. These outcomes far exceed existing treatment options, underscoring TIBSOVO’s potential as a transformative therapy for this patient population.
The potential approval of TIBSOVO as the first targeted therapy for IDH1-mutated MDS patients holds promise for improving their outcomes. It offers hope to the 3.6% of diagnosed patients who harbor this mutation and have historically faced limited treatment options, providing a pathway to enhanced survival rates and improved quality of life.